Your browser doesn't support javascript.
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi, Angela; Koch, Matthew; Wu, Kai; Dixon, Groves; Oestreicher, Judy; Legault, Holly; Stewart-Jones, Guillaume B E; Colpitts, Tonya; Pajon, Rolando; Bennett, Hamilton; Carfi, Andrea; Edwards, Darin K.
  • Choi A; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Koch M; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Wu K; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Dixon G; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Oestreicher J; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Legault H; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Stewart-Jones GBE; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Colpitts T; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Pajon R; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Bennett H; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Carfi A; Moderna, Inc., Cambridge, Massachusetts, USA.
  • Edwards DK; Moderna, Inc., Cambridge, Massachusetts, USA.
J Virol ; 95(23): e0131321, 2021 11 09.
Article in English | MEDLINE | ID: covidwho-1434895
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity. Sera from participants immunized on a prime-boost schedule with the mRNA-1273 COVID-19 vaccine were tested for neutralizing activity against several SARS-CoV-2 variants, including variants of concern (VOCs) and variants of interest (VOIs), compared to neutralization of the wild-type SARS-CoV-2 virus (designated D614G). Results showed minimal, statistically nonsignificant effects on neutralization titers against the B.1.1.7 (Alpha) variant (1.2-fold reduction compared with D614G); other VOCs, such as B.1.351 (Beta, including B.1.351-v1, B.1.351-v2, and B.1.351-v3), P.1 (Gamma), and B.1.617.2 (Delta), showed significantly decreased neutralization titers ranging from 2.1-fold to 8.4-fold reductions compared with D614G, although all remained susceptible to mRNA-1273-elicited serum neutralization. IMPORTANCE In light of multiple variants of SARS-CoV-2 that have been documented globally during the COVID-19 pandemic, it remains important to continually assess the ability of currently available vaccines to confer protection against newly emerging variants. Data presented herein indicate that immunization with the mRNA-1273 COVID-19 vaccine produces neutralizing antibodies against key emerging variants tested, including variants of concern and variants of interest. While the serum neutralization elicited by mRNA-1273 against most variants tested was reduced compared with that against the wild-type virus, the level of neutralization is still expected to be protective. Such data are crucial to inform ongoing and future vaccination strategies to combat COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Pandemics / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Adult / Female / Humans / Male Language: English Journal: J Virol Year: 2021 Document Type: Article Affiliation country: JVI.01313-21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Pandemics / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Adult / Female / Humans / Male Language: English Journal: J Virol Year: 2021 Document Type: Article Affiliation country: JVI.01313-21